Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.32 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGAV | P06756 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9098370 | 0.80 | RAB9A (0.43) | NNMTMAPTUHRF1MEN1RAB9A | |
| SCHEMBL6308267 | 0.74 | ACHE (0.41) | MAPTSIGMAR1CHRNB2CHRNA4ROCK1 | |
| SCHEMBL22743534 | 0.73 | ALDH1A1 (0.42) | NNMTUHRF1EHMT2MEN1RAB9A | |
| SCHEMBL22743004 | 0.73 | BACE1 (0.39) | NNMTUHRF1EHMT2MEN1RAB9A | |
| SCHEMBL6308105 | 0.72 | MAPT (0.52) | MAPTSIGMAR1CHRNB2CHRNA4ROCK1 | |
| SCHEMBL6307347 | 0.72 | MAPT (0.52) | MAPTSIGMAR1CHRNB2CHRNA4ROCK1 | |
| SCHEMBL22717228 | 0.72 | NNMT (0.35) | NNMTMAPTUHRF1EHMT2MEN1 | |
| SCHEMBL4119594 | 0.70 | CYP3A4 (0.44) | MAPTCHRNB2CHRNA4 | |
| SCHEMBL22743872 | 0.70 | UHRF1 (0.36) | NNMTUHRF1EHMT2MEN1RAB9A | |
| SCHEMBL14852740 | 0.69 | MAPT (0.45) | NNMTMAPTEHMT2MEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013082751-A1 | PHOSPHATE TRANSPORT INHIBITORS I | LEO PHARMA A/S (DK) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013082756-A1 | PHOSPHATE TRANSPORT INHIBITORS II | LEO PHARMA A/S (DK) | 2013-06-13 | — | — | WO | disclosed |
| US-20090023756-A1 | SUBSTITUTED QUINAZOLINES AS PDE10 INHIBITORS | PFIZER INC | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023756-A1 | SUBSTITUTED QUINAZOLINES AS PDE10 INHIBITORS | PDE12, PDE5A, PDE10A | NNMT 109/4885MAPT 349/4885SIGMAR1 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.